FogPharma
245 First Street, 18th Floor
Cambridge
Massachusetts
02458
United States
Tel: 617-444-8642
Website: http://www.fogpharma.com/
Email: info@fogpharma.com
About FogPharma
FogPharma is developing transformative new medicines exploiting the unique ability of cell-penetrating miniproteins to access validated "undruggable" intracellular disease drivers and to home in on therapeutically beneficial tissues in the human body.YEAR FOUNDED:
2015
LEADERSHIP:
Founder: Dr. Greg Verdine
17 articles about FogPharma
-
FogPharma Announces $145 Million Financing to Support Ongoing Clinical Development of FOG-001 and Accelerate Helicon Peptide Portfolio
3/1/2024
FogPharma®, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently available medicines using its Helicon™ peptide platform, announced the successful closing of a $145 million Series E financing round.
-
FogPharma’s latest financing round will help fund the ongoing clinical development of the company’s potential first-in-class intracellular TCF-blocking β-catenin inhibitor being evaluated in a Phase I/II study.
-
FogPharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/4/2024
FogPharma today announced that Mathai Mammen, M.D., Ph.D., chairman, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 3:30 p.m.
-
FogPharma Announces First Patient Dosed in Phase 1/2 Clinical Trial of First-in-class TCF-blocking β-catenin Inhibitor, FOG-001, in Advanced Solid Tumors
6/5/2023
FogPharma today announced the first patient has been dosed in a first-in-human Phase 1/2 clinical trial of, FOG-001, the company’s first-in-class TCF-blocking β-catenin inhibitor.
-
Nearly eight months after leaving his post as head of R&D at Johnson & Johnson, Mathai Mammen has found a new job as CEO of cancer focused FogPharma.
-
Mathai Mammen, M.D., Ph.D., to Join FogPharma as Chairman, President and Chief Executive Officer
3/30/2023
FogPharma®, a biopharmaceutical company committed to transforming the lives of patients through a new precision medicine approach widely applicable to important and challenging intracellular targets, announced that Mathai Mammen, M.D., Ph.D., will join the company as chairman, president and chief executive officer.
-
FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers
11/21/2022
FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” today announced a $178 Million Series D financing.
-
FogPharma Announces Selection of Clinical Development Candidate Directly Targeting β-Catenin
3/9/2022
FogPharma, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to all therapeutic targets, including those previously considered “undruggable,” today announced the selection of its lead product development candidate, FOG-001, a first-and-only-in-class direct β-catenin inhibitor.
-
FogPharma Expands Executive Leadership Team
11/22/2021
FogPharma today announced the appointments of Lihua Yu, Ph.D., as chief data officer and Keith Orford, M.D., Ph.D., as chief medical officer and executive vice president of clinical and translational science.
-
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
3/1/2021
FogPharma ® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability ™ Platform FogPhama’s proprietary Helicon™ peptides represent a new class of precision medicines that combines the targeting strength and specificity of antibodies with the cell penetration of small molecules
-
FogPharma Appoints Tony Gibney as Chief Financial Officer and Chief Business Officer
5/7/2020
FogPharma today announced the appointment of Tony Gibney as Chief Financial Officer and Chief Business Officer.
-
Cambridge Discovery Park Building 400-500 Will be New Headquarters for FogPharma and LifeMine Therapeutics
6/12/2019
The Bulfinch Companies, Inc. announced it has signed a 114,490 SF lease with FogPharma in building 400 at Cambridge Discovery Park.
-
BioSpace Movers and Shakers: May 10
5/10/2019
Pharma and biotech companies strengthen their leadership teams with new hires at Immunocore, Eisai, Kyn, Bicycle, and more. -
FogPharma Strengthens New Modality Drug Hunting Team with Appointment of Howard Stern as Chief Scientific Officer and Peter Fekkes as Vice President of Discovery Bioscience
5/6/2019
FogPharma announced the appointment of Howard Stern, M.D., Ph.D., as Chief Scientific Officer.
-
FogPharma Appoints Dr. Barbara Weber to its Board of Directors
10/25/2018
CEO of Tango Therapeutics and Venture Partner at Third Rock Ventures to lend her expertise to FogPharma as the Company continues to advance a powerful new class of medicines - cell-penetrating miniproteins - for the treatment of serious diseases
-
FogPharma Secures $66 Million Series B Financing
5/16/2018
Company is pioneering a powerful new class of medicines - cell-penetrating miniproteins - with an on-demand drug discovery platform for the treatment of serious diseases driven by intractable targets
-
Serial Biotech Entrepreneur to Helm Biotech Startup FogPharma After Retiring From Harvard
2/24/2017